



Contents lists available at ScienceDirect

Saudi Pharmaceutical Journal

journal homepage: www.sciencedirect.com



Original article

Synthesis of hydrazides of heterocyclic amines and their antimicrobial and spasmolytic activity

Dmitriy A. Berillo^{a,b,*}, Moldyr A. Dyusebaeva^b^a Division of Chemistry, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan^b Department of Pharmaceutical and Toxicological Chemistry, Pharmacognosy and Botany School of Pharmacy Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan

ARTICLE INFO

Article history:

Received 11 October 2021

Accepted 12 April 2022

Available online 26 April 2022

Keywords:

Piperidine and morpholine derivatives

Hydrazides of α - & β -amino acids

Antimicrobial activity

Spasmolytic activity and acute toxicity

SAR

ABSTRACT

Un solvable issue of a significant number increase of drug multi resistant strains of microorganisms including Mycobacterium tuberculosis force researchers for continuous design novel pharmaceuticals.

The purpose of the study is the establishment of the correlation between the structure of novel heterocyclic hydrazide derivatives and their biological activity. Several hydrazide derivatives of N-piperidinyl and N-morpholinyl and propionic acids and N-piperidinyl acetic and their derivatives were synthesized via condensation of corresponding esters with hydrazine hydrate. The structure of synthesized compounds were confirmed by the use of FTIR, ¹H NMR, Mass-spectroscopy and element analysis. Investigation of synthesized substances using PASS software was carried out to predict probability of pharmacological activity in silico. The antibacterial, antifungal and spasmolytic activity as well as acute toxicity of obtained compounds were evaluated in vivo. 2-(N-piperidinyl)acetic acid hydrazide and 2-methyl-3-N-piperidinyl)propanoic acid hydrazide revealed antibacterial and spasmolytic activities comparable to the model drugs (drotaverin) *in vitro* study. Synthesized compounds in *in vivo* experiment showed significantly low acute toxicity (LD₅₀ 520–5750 mg/kg) compared to commercially available drugs (streptomycin, ciprofloxacin and drotaverin LD₅₀ 100–215 mg/kg). The structure- activity relationship was established that the increasing of the length of the linker between heterocyclic amine and hydrazide group results in a decrease of antimicrobial activity against studied strains (*Escherichia coli*, *Salmonella typhimurium*, *Salmonella choleraesuis*, *Staphylococcus aureus*).

© 2022 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Past several decades illustrated a growing interest to synthesis of novel precursors of drugs and modification of commercially available drug due to unsolvable issue with an increasing number of drug multi resistant strains of microorganisms including Mycobacterium Tuberculosis (Gegia, Winters et al. 2017, Vilchêze and Jacobs Jr 2019, Zhang, Jiang et al. 2019) and advances in medicine related to discovery of new diseases. Moreover, a synthesis of novel active pharmaceutical substances have a great interest for

development of fundamental organic chemistry and drug discovery the establishment of a relation between 3-D structure of isomers and their biological activity. Moreover, the rising interest in fundamental relationship between 3-D structure of organic compounds and their biological activity facilitates the need for the synthesis of new active pharmaceutical substances (Domagala 1994, Dudek, Arodz et al. 2006, Koçyigit-Kaymakçioğlu, Oruç-Emre et al. 2009, Roveda, Clavette et al. 2009, Popiołek 2017). The interest of the synthesis of novel heterocyclic amines and particularly to hydrazide derivatives of piperidine and morpholine is attributed to their wide biological activity. The particular interest is in the synthesis of piperidine and morpholine derivatives due to their wide spectrum of biological activity (Eswaran, Adhikari et al. 2009, Pillai, Rajeswari et al. 2014, Jachak, Ramesh et al. 2015, RK, BEGUM et al. 2018, Tikhov and Kuznetsov 2020). A recent review paper illustrated comprehensive overview of chemical modifications (Dieckmann cyclization, Mannich reaction/amidation, Diels-Alder reaction, δ -amino- β -ketoester condensation etc.) including enolate-carbodiimide rearrangement of piperidine and

* Corresponding author.

E-mail address: berillo.d@kaznmu.kz (D.A. Berillo).

Peer review under responsibility of King Saud University.



<https://doi.org/10.1016/j.jsps.2022.04.009>

1319-0164/© 2022 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

piperidine-2,4-dione derivatives. For these structures various biological activities were found as selective inhibitors of the enzymes dihydroorotase and thiodihydroorotase, that is promising for the development of anti-cancer drugs and antimicrobial substances (Tikhov and Kuznetsov 2020). Quantitative structure–activity relationship (QSAR), Structure–Activity Relationship (SAR) and other modern methods provide opportunity to predict potential biological activity prior testing it *in vitro* and *in vivo* (Alanine, Anselm et al. 2004, Dudek, Arodz et al. 2006, Roveda, Clavette et al. 2009, El-Shamy, Abdel-Mohsen et al. 2015, Mathew, Suresh et al. 2015, Sader, Castanheira et al. 2017, RK, Belgum et al. 2018). A number of highly active and at the same time quite toxic compounds were found among hydrazide derivatives of pyridine and other aromatic compounds (Sievers and Herrier 1975, Alanine, Anselm et al. 2004, Karaman, Oruç-Emre et al. 2016), therefore the search of less toxic and sufficiently active compounds remains a relevant problem of pharmaceutical chemistry (Ross 1958). For example, carbonic acid hydrazides (isonicotinic acid hydrazide) cause clinically apparent acute liver injury, that increase from 0.5% to 1% and is fatal in the range of 0.05–0.1% to the recipients (Shah, Santucci et al. 1995). Isoniazid and their derivatives were discovered and comprehensively studied in the middle of 20th century (Middlebrook 1954; Rollas and Küçükgüzel, 2007). A great interest to carbonic acid hydrazides and thiohydrazides is related to simplicity of their synthesis and purification process as well as its high chemical reactivity (Alanine, Anselm et al. 2004, Mathew, Suresh et al. 2015). Products of hydrazides condensation with aldehydes - hydrazones revealed a wide range of antimicrobial, antiviral, antitumor, hypolipidemic, hypotensive, diuretic activities and activity against M. Tuberculosis at a relatively low toxicity (Sievers and Herrier 1975, Alanine, Anselm et al. 2004, Narang, Narasimhan et al. 2012, Pillai, Rajeswari et al. 2014, Karaman, Oruç-Emre et al. 2016). Derivatives bearing a R-CONHR functionality at the 6-position of naphthyridine exhibited analgesic and/or anti-inflammatory activities (Di Braccio, Grossi et al. 2014). The reports describe antimicrobial, antioxidant, antimicrobial and antioxidant activity of various morpholine derivatives being attributed to Schiff bases and β -lactam functionalities. (Cebeci, Bayrak et al. 2019) It was reported that glycine hydrazides derivatives possess high spasmolytic activity, transient hypotension and might have effects on the central nervous system and revealed low toxicity with LD50 more than 1000 mg/kg (Rips, Derappe et al. 1965). A detailed method of synthesis of thiosemicarbazides of N-piperidinylacetic acid was described previously as well as strategies of its cyclisation to bisheterocyclic compounds (Misra, Dwivedi et al. 1978, Dyusebaeva and Kalugin 2015). In this work the synthesis of various hydrazides containing heterocyclic amine is described and results of antimicrobial, antifungal and spasmolytic activity as well as acute toxicity is discussed.

2. Materials and methods

2.1. Chemistry

Hydrazine hydrate (50%) and 3,4-Dihydroxybenzaldehyde (97%); CD₃OD (99.9%), DMSO *d*₆ (99.9%); drugs of comparison: Amphotericin B solution (250 μ g/mL in deionized water, 0.1 μ m filtered, BioReagent), Miconazole (\pm)-1-[2-(2,4-Dichlorobenzoyloxy)-2-(2,4-dichlorophenyl)-ethyl]-1H-imidazole, streptomycin (99.5%), ciprofloxacinum (1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-quinoline-3-carboxylic acid) (99%); dro-taverin (1-[(3,4-diethoxyphenyl)-methylene]-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (99%)), TLC Silufol UV-254 were obtained from Aldrich Chemical Co. KBr (99.5%), ethanol (95%), hexane (99%), benzene (99%), dichloromethane (99%), hydrochloride

(95%) and iodine (98%) were obtained from LabChemProm, which was then converted to absolute ethanol using a distillation with calcium oxide (technical grade). Prior to use all reagent were purified via distillation under reduced pressure. The control of purity of synthesized derivatives was controlled using TLC Silufol UV-254 (treatment with a vapour of iodine) (Tolstikova, Tolstikov et al. 1988).

FTIR spectra of obtained compounds were recorded using Spedcord 75 IR spectrophotometer (in a thin layer, in tablets with KBr) with a resolution 2 cm^{-1} .

¹H NMR spectroscopy (Bruker 300 NMR spectrometer, USA Bruker, and Bruker DRX 500 with a working frequency of 300, 500 MHz). Internal standard for ¹H NMR was hexamethyldisilane, deuterated solvents CD₃OD, DMSO *d*₆ was used for dissolution of compounds.

Agilent 6890 N-5973 N GC-MS (Palo Alto, CA, USA) with electronic ion sources was used for characterisation of novel compounds. The analysis was performed on a Agilent 6890N gas chromatograph equipped with Agilent 5973 N mass selective detector. Capillary GC analysis was carried out on a HP-5MS (30 m \times 0.25 mm ID, 0.25 μ m) capillary column (5% diphenyl, 95% dimethylpolysiloxane, J&W Scientific, Folsom, CA, USA) with helium as mobile phase. Quadrupole analyzer temperatures were maintained at 280, 230, 180 °C. A solvent delay of 3 min was chosen. In the full-scan mode, electron ionization (EI) mass spectra in the range of 50–500 (*m/z*) were recorded.

2.2. Synthesis of aminoheterocyclic acids hydrazides (I-V)

Synthesis of ethyl(methyl) esters of α - β - aminocarbonic acid (I-IV) were conducted according to previously described methods (Berillo and Sh.S. 2008, Berillo 2010, Dyusebaeva and Kalugin 2015). Briefly, piperidine or morpholine dissolved in absolute ethanol was added dropwise to the solution of methylacrylate or methylmethacrylate, which was taken with a 10% excess compared to heterocyclic amine under stirring at room temperature. The reaction mixture was incubated at elevated temperature overnight and the color change from transparent to reddish appeared. The solvent and unreacted initial compounds were removed under reduced pressure. The lead products were purified *via* distillation under vacuum. A reaction mixture containing 0.1 mol of ethyl (methyl) esters of α - β - heterocyclic amino functionality (morpholinyl or piperidinyl) acetic or propan acid, 6 g (0.12 mol) absolute hydrazine hydrate (95%) reflux in ethanol for 2 h at 75–80 °C. The kinetic of product formation was monitored using TLC. Compounds DB (III-V) were purified using a column chromatography with silica gel eluent of absolute ethanol or methanol. After evaporation of solvent under vacuum a crystal products were obtained. The compound MAI was synthesised according to the report, [Alanine, A., et al. 2004] piperidine was treated with ethyl ester of bromoacetic acid in presence of potassium carbonate. Then, the product ethyl ester of 2-(N-piperidyl) acetic acid was reacted with the hydrazine hydrate. Analogously 2-(4-hydroxylimino)-2,5-dimethyl piperidin-1-yl) was alkylated by ethyl ester of bromoacetic acid in acetone medium in the presence of dry potassium carbonate. Obtained ester of 2-(4-hydroxylimino)-2,5-dimethyl piperidin-1-yl)acetic acid was reacted with hydrazine hydrate giving the substance MAII.

2-(N-piperidyl) acetic acid hydrazide (MAI) C₇H₁₅N₃O Mr 157.21 g/mol, white crystals, yield 95.9%; m.p. 55–56 °C. FTIR, ν , cm^{-1} : 1245 (C–O–C), 1735 (>C = O), 3422–3254 (–NH–NH₂). ¹H NMR (DMSO *d*₆), δ , ppm: 1.3 (s, 2H, –CH₂–), 1.5 (s, 4H, 2–CH₂–), 2.1 (s, 4H, 2–CH₂–), 2.4 (d, 2H, –NCH₂–), 3.8 (d, 2H, –NH₂), 8.1 (s, 1H, –NH–) (Bruker 300 NMR spectrometer, USA Bruker with a working frequency of 300 MHz). Elemental analysis of C₇H₁₅N₃O,

%: experimental C 53.43; H 9.54; N 26.72; theoretical C 53.50; H 9.44; N 26.53.

2-(4-hydroxyimino)-2,5-dimethyl piperidin-1-yl)acetic acid hydrazide (MAII) $C_9H_{20}N_4O_2$, 216.27 g/mol, white crystals, yield 80% and m.p. 151–152 °C. FTIR, ν , cm^{-1} : 1245 (C–O–C), 1620 ($>C = N-$), 1732 ($>C = O$), 3420–3250 ($-NH-NH_2$). 1H NMR (DMSO d_6), δ , ppm: 1.3 (d, 2H, $-CH_2-$), 1.5 (d, 4H, 2- CH_2-), 2.1 (d, 4H, 2- CH_2-), 1.10 and 0.9 (d, 3H, 2- CH_3 ; d, 3H, 5- CH_3), 2.4 (s, 2H, $-NCH_2-$), 3.5 (qt, 1H, $-C^2H-CH_3$), 2.2 (qt, 1H, $-C^5H-CH_3$), 3.8 (d, 2H, $-NH_2$), 8.3 (d, 1H, $-NH-$), 9.58 (s, 1H, $>N-OH$). Elemental analysis %: experimental C 50.64; H 8.36; N 25.87. $C_9H_{18}N_4O_2$; theoretical C 50.45; H 8.47; N 26.15.

2-methyl-3-(N-piperidyl)propionic acid hydrazide (BDIII), $C_9H_{19}N_3O$ 185.27 g/mol, white crystals, m.p. 90–91 °C and R_f (benzene: EtOH 1:1) 0.23, yield of 95%. The product was purified using column chromatography on silica gel applying eluent benzene: EtOH 1:1. FTIR, ν , cm^{-1} : 1675 ($>C = O$), 3422.5–3254 ($-NH-NH_2$), $-CH_2-$, $-CH_3$ 2962 and 2914. 1H NMR (DMSO d_6), δ , ppm: 1.58 (ddd, 6H, $-CH_2^{3,4,5}$) and 2.34 (dd, 4H, $-CH_2^{2,6}$), 2.05 (qt, 1H, $-CH-CH_3$), 1.1 (d, 3H, $-CH-CH_3$), 1.62 (d, 2H, $>N-CH_2-$), 8.84 (d, 1H, $-NH-$), 10.92 (s, 2H, $-NH_2$). Mass-spectrum main pattern, m/z (I relative): 186 (0.01%), 171 (0.1116), 170 (0.09), 169 (0.025), 161 (0.01), 149 (0.01), 142 (0.025), 130 (0.025), 126 (0.05), 124 (0.08), 110 (1.116), 99 (6), 98 (100), 96 (3.53), 86 (1.76), 85 (5.88), 84 (10.58), 70 (4.7), 69 (3.5), 57 (1.76), 56 (3.6), 55 (7), 45 (2.3), 44 (3.3), 42 (7), 41 (7), 39 (2.9) (Figure S1).

2-Methyl-3-(N-morpholyl)propionic acid hydrazide (BDIV) $C_8H_{17}N_3O_2$ Mr 187.24 g/mol, yield of 80%, white crystals, m.p. 69 °C and R_f 0.31 (benzene: EtOH 1:1). FTIR, ν , cm^{-1} : 1675 ($>C = O$), 1125 (C–O–C), 3424–3260 ($-NH-NH_2$). 1H NMR (DMSO d_6), δ , ppm: 1.14–1.16 (d, 3H, $-CH(CH_3)$), 2.78–2.74 (qt, 1H, $-CH(CH_3)$), 3.71–3.65 (qt, 4H, 2($-OCH_2-$)), 2.32–2.29 (ddd, 4H, 2($-CH_2-$)), 2.6–2.44 (d, 2H, $-NCH_2-$). Mass-spectrum main pattern, m/z (I relative): 187 (3.33%), 172 (0.66), 156 (0.66), 144 (0.66), 128 (1), 112 (0.66), 101 (7), 100 (100), 98 (7.3), 87 (2.5), 86 (3), 82 (1), 72 (2.5), 70 (7.5), 69 (4), 68 (3), 58 (2.5), 57 (5), 56 (15), 55 (5), 54 (2.5) (Figure S2).

3-(N-morpholyl)propionic acid hydrazide (BDV) $C_7H_{14}N_3O_2$ Mr 186.2 g/mol, yield of 70%, m.p. 66–69 °C and R_f 0.34 (benzene: EtOH – 1:1). FTIR, ν , cm^{-1} : 1669 ($>C = O$), 1115 (C–O–C), 3420–3250 ($-NH-NH_2$). 1H NMR (DMSO d_6), δ , ppm: 2.47 (t, 2H, $-CH_2-$), 2.86 (m, 4H, 2- CH_2-), 3.65 (m, 4H, 2($-OCH_2-$)) 4.15 (t, 2H, $>NCH_2-$), 8.97 (d, 2H, $-NH_2$).

3,4-dihydroxybenzylidenhydrazide 2-methyl-3-(N-piperidyl)propionic acid (DBVI) $C_{16}H_{23}N_3O_3$ Mr 305.37 g/mol. The reaction mixture containing 1.85 g (0.01 mol) of 2-methyl-3-(N-morpholyl)propionic acid hydrazide (BDIV) was solubilised in absolute ethanol and mixed with (0.01 mol) 3,4-dihydroxybenzaldehyde dissolved in 20 ml of ethanol and incubated at room temperature for 6 h. The kinetics of product formation were monitored using TLC. After the initial compounds disappear from TLC the solvent was evaporated under vacuum at 50 °C, the obtained crude product was mixed with silica gel and purified using column chromatography CH_2Cl_2 –hexane. Melting point 170–172 °C, R_f 0.303 (EtOH 96%), brown crystals, yield 46%. FTIR, ν , cm^{-1} : 1625 ($>N = CH$); 3209 ($>NH$); 1625 ($>C = O$); 3387 ($-OH$); 1598, 1510, 1494; ($-C = C$ –aromatic), 3055 (C–H aromatic). 1H NMR (DMSO d_6) (δ , ppm): 7.95 (s, 1H, $-CH = N-$), 2.52–2.55 (2H, $-N-CH_2-$), 2.38–2.27, 2.13–2.06 (m, 4H, $-CH_2^{2,6}$), 1.46–1.44 and 1.41–1.35 (m, 6H, $-CH_2^{3,4,5}$), 3.61 (qt, 1H, $-CH(CH_3)$), 1.04–1.02 (d, 3H, $-CH(CH_3)$), 7.16–7.09 (dd, 1H, 6-Ar–H), 6.88–6.87 (dd, 1H, 5-Ar–H), 6.75–6.73 (dd, 1H, 2-Ar–H), 10.89 (s, 1H, $-OH$). MS: m/z 305 (M^+). Mass-spectrum main pattern, m/z (I

relative): 305, 288, 267, 207, 194, 171, 134, 121, 112, 105, 98 (100%), 91, 86, 85, 77, 55, 51 (Figure S3).

2.3. In silico study

Prediction of Activity Spectra for Substances (PASS) predicts 4000 types of biological activity with the average prediction accuracy of about 95%. (Stasevych, Zvarych et al. 2017) <http://www.way2drug.com/passonline/> Physicochemical properties, LogP and Lipinski constants of compounds (I–VI) calculated using Advanced Chemistry Development (ACD/Labs) Software V11.0 are provided in supplementary information.

2.4. Biological assays

Antimicrobial and spasmolytic activity as well as acute toxicity of 2-(4-dihydroxyimino)-2,5-dimethyl piperidyl) acetic acid hydrazide (II); 2-methyl-3-(N-piperidyl)propionic acid hydrazide (III); 2-methyl-3-(N-morpholyl)propionic acid hydrazide (IV) were studied at the laboratory of Scientific and Production Association «MedBioPharm» (Almaty, Kazakhstan).

Antibacterial activity of compounds (I–IV) was evaluated against gram-positive (*S. aureus*) and gram-negative (*E. coli* and *S. choleraesuis*, *S. Typhymurium*,) bacterial strains. The growth of microorganisms was determined on the meat and peptone broth and expressed through a turbidity standard procedure calibrated from 0 to 4. The score 4 is attributed to (control) the turbidity of the meat and peptone solution with bacterial growth (over 1 million microbial cells/ ml of broth), score 3 corresponds to the range of concentrations from 1,000 up to 1 million cells/mL, score 2 is related to the range - from 50 to 1000 cells/mL, score 1 contains up to 50 microbial cells/mL, Score 0 - a clear solution indicating strong bacteriostatic activity. Streptomycin was used as a reference drug (control) in comparable concentration (Dyusebaeva, Elibaeva et al. 2017). Antimicrobial activity of 3-(N-morpholyl)propionic acid hydrazide (V) and 3,4-dihydroxybenzyliden hydrazide 2-methyl-3-(N-piperidyl)propionic acid (VI) were investigated at the laboratory of microbiology at Department of Biotechnology Al-Farabi Kazakh National University (Almaty, Kazakhstan). The antibacterial activity of compounds V and VI was tested against strains of *E. coli* 251, *S. Typhymurium*, *S. choleraesuis*, *S. aureus* on meat and peptone broth by serial dilution. Incubation of tubes containing medium with and without precursor of drug was carried out at 37 °C. The results of bacteriostatic activity were considered after 24, 48, 72 h, respectively. A comparable concentration of antibiotic drug ciproflaxacinum was used as a control according to the standard protocol (Gein, Odegova et al. 2015). The compound III at concentration of 0.2 mg/mL was tested against antifungal activity, against *C. albicans*, *A. flavus*, *M. canis*, *F. solani*, *C. glabrata*. The incubation of plates was performed for 7 days at 27 °C (Mittendorf, Kunisch et al. 2003).

The spasmodic activity was estimated using a model of intestine of white Outbred laboratory rats according a recognized method *in vitro* (Kulkarni, Patil et al. 2004). Briefly, the experiment was performed using male rats of the same age and weight. A segment of the intestine with a length of about 3 cm was used, purified of contents and connective tissue. The measurements of contraction or release of the intestine was conducted using a device for working with isolated organs manufactured by Ugo Basile (Italy). The lower end of the intestinal fragment was fixed on a hook in a Tyrode solution [47] at a temperature of 37 °C. After the test the active pharmaceutical substance was introduced into the cuvette, the degree of intestinal contraction was recorded. Compounds with high antispasmodic activity, showed no change

in intestinal length or the smallest degree of contraction. As a reference a well-known drug drotaverin (brand name No-shpa) was used.

The acute toxicity LD₅₀ of active pharmaceutical substances (I–IV) was studied by intraperitoneal administration using white outbred mice of both sexes weighing 17–23 g (n = 3) according to previously published method (Hooser, Beasley et al. 1989). The preclinical animal studies were carried out at the organisation “MedBioPharm” (Almaty, Kazakhstan). All animal studies were performed according to the general guidelines of working with animals “Rules of the European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes” and in accordance with the requirements for the study of new pharmacological substances (Council 2010, Council 2011).

3. Results and discussion

3.1. Synthesis

Piperidine and morpholine containing α - & β -amino propionic acid hydrazides were synthesized.


using a well-known method of ester group condensation with hydrazine hydrate. The esters of α - & β aminoacids were obtained via nucleophile addition reaction of piperidine or morpholine to the double bond of acrylic(methacrylic) acid esters (Berillo 2010, Dyusebaeva and Kalugin 2015). The reflux of the ester of α - or β -aminoacids with hydrazine hydrate for several hours leads to corresponding hydrazides (Scheme 1).

The structures of synthesized compounds are presented on the Fig. 1. Comprehensive physicochemical characterization is shown in experimental part and supplementary information. The FTIR spectrum of pharmaceutical active substance 2- (N-piperidinyl) acetohydrazide(MAI) contains absorption bands of stretching vibrations of the NH₂ group in the region of 3310–3260 cm⁻¹, the NH group in the region of 3180 cm⁻¹, and the carbonyl group at 1690 cm⁻¹. In the 1H NMR spectrum of the BDIII, the protons of the piperidine ring resonate at the field of 1.58 ppm (ddd, 6H, –CH₂3,4,5) and 2.34 ppm (dd, 4H, –CH₂2,6). Protons at carbon atoms C_{2,6} are shifted to the region of downfield due to the influence of the nitrogen atom and appear at δ 2.34 ppm. Multiplets in a upfield at δ 1.58 ppm and δ 1.60 ppm belong to the C₄ and C_{3,5} protons of the carbon atoms of the piperidine fragment of the molecule. The doublet signal at 1.1 ppm attributed to the proton of the methyl group (–CH–CH₃–C(=O)), doublet signal of methylene group (>N–CH₂–CH–(CH₃)) appears at 1.62 ppm and the quadruplet signal of proton (–CH–CH₃) was observed at 2.05 ppm. The IR spectrum of pharmaceutical active substance 2-methyl-3-(N-morpholinyl)propanoic acid hydrazide (BDIV) contains absorption bands of stretching vibrations of the primary amino group at 3434 cm⁻¹ and of the NH group of an amide character in the region of 3222 cm⁻¹, the carbonyl group appears at 1669 cm⁻¹, as well as an absorption frequency at 1115 cm⁻¹ is related to the stretching vibrations of the C–O–C morpholine cycle. 1H NMR spectrum of BDIV contains the protons of the morpholine ring resonating in the form of doublets at δ 2.29–2.32 and 3.65–3.74 ppm, respectively. Doublet signals of methylene groups C_{2,6} are shifted to the region higher frequency field due to the influence of the nitro-

gen atom and appear at 2.29–2.32 ppm. Signals at 3.65 and 3.74 ppm attributed to the protons C_{3,5} of the methylene groups of the morpholine fragment of the molecule BDIV deshielded, due to the influence of the electronegative oxygen atom. The 3 protons of the methyl group (–CH–CH₃) appears as a doublet signal at 1.14 ppm, and one proton (–CH–CH₃) registered as a quadruplet signal at 2.74–2.78 ppm. The methylene protons of the N–CH₂ resonate as doublet signal in the field of 2.44–2.60 ppm in the substance BDIV. Due to the fact that the 1H NMR spectrum was recorded in a protonic solvent D₂O, the protons of the NH₂ and NH groups are not identified in the spectrum, as these protons are attributed to easily exchangeable.

3.2. Pharmacological activity

The main scope of the current research is focused on the establishment of the correlation between the structure of novel heterocycle derivatives hydrazides and their biological activity (spasmolytic, antimicrobial, antifungal). Estimation of the acute toxicity is also an important parameter taken into account during novel pharmaceutical development. Results of acute toxicity, spasmolytic and antimicrobial activity of novel derivatives (MAI; 2-(4-hydroxyimino)-2,5-dimethyl piperidin-1-yl)acetic acid hydrazide (MAII); 2-methyl-3-(N-piperidyl)propionic acid hydrazide (BDIII) and BDIV) is presented in Table 1. Biological activity and the toxicity of compounds were compared to activity of model well known drugs ciprofloxacinum (antimicrobial activity), drotaverin containing piperidine fragment as spasmolytic substance. The toxicity of heterocyclic derivatives of hydrazides (MAI, MAII, BDIII, BDIV) revealed significantly lesser acute toxicity compared to model drugs (Table 1). In order to carry out the real correlation of toxicity to quantity of the active pharmaceutical substance the LD₅₀ was represented in mmol/kg of mouse. In average synthesized drugs exhibited more than hundred times less toxicity in comparison with the model drugs (Streptomycin, Ciprofloxacin, Drotaverine) (Table 1). Obtained compounds have different pK_a values (S4) and therefore pH of solutions in pure water were 11–9 and adjusted with hydrochloric acid to physiological values. It is known that the inhibitory activity of some substances is pH dependent due to existence of a mixture of tautomeric forms and one has different pharmacological activity to the other (Tikhov and Kuznetsov, 2020). Lipinski parameters helps to estimate druglikeness or evaluate if a derivative has a certain pharmacological or biological activity, as well as prognoses chemical and physical properties that would likely make it an orally active drug (Lipinski, Lombardo et al. 1997). Therefore, we provided entirely essential parameters prediction of biological activity such as polar surface area, solubility, pK_a, pH of the unbuffered solution and LogP obtained using Advanced Chemistry Development (ACD/Labs) Software (supplementary information). Calculated Lipinski's parameters for the synthesized compounds are in a correct range of values (no more than 5 hydrogen bond donors (the total number of nitrogen–hydrogen and oxygen – hydrogen bonds); no more than 10 hydrogen bond acceptors (all nitrogen or oxygen atoms) a molecular weight less than 500 g/mol) and therefore we can expect biological activity (Lipinski, Lombardo et al. 1997).



Scheme 1. Synthesis of N substituted amino acid hydrazides.




Fig. 1. Structures of active pharmaceutical substances piperidine and morpholine derivatives.

Table 1
Acute toxicity and antimicrobial activity of novel compounds (MAI; MAII; BDIII and BDIV).

Pharmaceutical active substance	LogP	LD ₅₀ , mmol/kg	LD ₅₀ , mg/kg	Antimicrobial activity		
				<i>S. choleraesuis</i>	<i>E. coli</i>	<i>S. aureus</i>
MAI	-0.716	3,67	580	0	1	0
MAII	-1.043	2.40	520	3	4	4
BDIII	-0.254	4.31	greater than 800	2	2	2
BDIV*	-1.834	30.73	5755 ±21	4	4	4
BDV	-2.118	-	-	4	4	4
Streptomycin	-6.4	3.676 E-4	213.8	0	0	0
Ciprofloxacin	-1.1	2.966E-4	98.3	0	0	0
Dotraverine	-	37.7 E-3	15	-	-	-
Negative control	-	-	0	4	4	4

*LD₅₀ with intraperitoneal administration to rats is equaled to 331 ± 11.5 mg/kg. 1.91 ± 0.066 mmol/kg.

3.3. Structure activity relationships

In vivo toxicity was decreased with the substitution of a piperidinyl group to a morpholinyl one (Table 1). This transition also diminished the antimicrobial activity, which is in line with the precisely reported data. It was established that the substitution of piperidinyl moiety to morpholinyl functionality.

resulted in the decrease of the toxicity in vivo. The transition from the piperidinyl to morpholinyl group led to diminish of antimicrobial efficiency, (Table 1) that correlates with previous studies containing morpholinyl cycle (Sensi, Maggi et al. 1964). Partition coefficient LogP is an important parameter taken into account during drug design, allowing to predict some biological activity as well as adsorption and distribution of the drug within the body (Ben Arfa, Combes et al. 2006). The compound MAII and ciprofloxacinum have similar LogP and polar surface area, however MAII did not reveal significant antimicrobial activity. Compounds MAI, MAII, BDIII and 3-(N-morpholinyl)propionic acid hydrazide (BDV) have LogP in the range of -2.1 - -0.25 and belongs to a group of relatively hydrophilic and well soluble compounds. It is known that too hydrophilic compounds with LogP less than -0.4 are less likely to possess antimicrobial activity and at the same time have low toxicity which is in a good agreement with obtained results (Table 1). It is known that some derivatives of hydrazides possess antimicrobial activity against *S. aureus* strains (Pillai, Rajeswari et al. 2014). Recently, β-amino acid revealed the most favourable activity-tolerability profile and was chosen for clinical studies as a novel antifungal for the oral treatment of yeast infections (Pillai, Rajeswari et al. 2014, Jachak, Ramesh et al. 2015). Therefore, we decided to test β-amino acid derivative for antifungal activity. 2-methyl-3-(N-piperidinyl)propionic acid hydrazide

(BDIII) at the concentration of 0.2 mg/mL, that, however did not reveal antifungal activity against 5 studied strains (Table S1). Antimicrobial activity of compounds MAI, MAII, BDIII, BDIV, BDV and 3,4-dihydroxybenzylidenehydrazide 2-methyl-3-(N-piperidinyl)propionic acid (BDVI) were tested on Gram positive and negative strains (*Escherichia coli* 251, *S. choleraesuis*, *S. Typhimurium*, *S. aureus* F-21). It was found that most active compounds are MAI, MAII, BDIII having a pharmacophore piperidinyl functionality and hydrazide group (-NH-NH₂) in the structure (Table 1). 2-methyl-3-(N-piperidinyl)propionic acid hydrazide BDIII possesses a moderate antimicrobial activity compared to the model drug streptomycin, but it is significantly less toxic and therefore it is possible to continue the investigation the antimicrobial activity at higher doses. These data correlate well with SAR data obtained using PASS software. Thus, antituberculous, antimycobacterial and antiviral (Picornavirus) probability of biological activity (Pa) for MAI were 0.541, 0.539 and 0.431, respectively. The computer modelling has revealed high probability for antituberculous (Pa 0.433) antimycobacterial (Pa 0.424) and antiviral (Picornavirus) (Pa 0.398) activity for the substance BDIII. Nevertheless, the derivative MAII has Pa coefficient of 0.373 for antibacterial activity the software did not predict antituberculous or antimycobacterial activity. Pharmaceutical active substance BDIV is very perspective for further investigation for antituberculous (Pa 0.418) antimycobacterial (Pa 0.41) and antiviral (Picornavirus) (Pa 0.41) activities. The morpholine containing derivative IV did not reveal inhibiting activity against bacterial strains *E. coli*, *S. Typhimurium*, *S. choleraesuis* and *S. aureus*. 2-(N-piperidinyl)-propionic acid hydrazide MAI revealed comparable level of antimicrobial activity of model drug ciprofloxacin. Previously, several 1,2,5-trimethylpiperidin-4-ol derivatives the precursor of MAII

were investigated for antibacterial activity of against 16 strains illustrating effective bacteriostatic effect at concentration of 50 mg/mL (Dyusebaeva, Elibaeva et al. 2017). 3-(N-morpholyl) propionic acid hydrazide BDV at concentrations of 0.5, 1.0, 2.0 and 4.0 mg/mL did not reveal the antimicrobial activity against E. coli 251 and S. aureus F-21 strains, respectively, which may be related with too hydrophilic structure (LogP -2.118). 3,4-dihydroxybenzilidenhydrazide 2-methyl-3-(N-piperidinyl)propionic acid DBVI possesses antimicrobial activity comparable to ciprofloxacin and the initial hydrazide DBIII. Thus, the introducing of aromatic ring into the molecule did not increase nor decrease antimicrobial activity significantly compared to initial hydrazide BDIII, however LogP changed significantly from -0.25 to $+1.4$ and polar surface area from 58 to 100A2 (Supplementary). The derivative BDVI at the concentration of 2 mg/mL illustrated bacteriostatic activity against S. aureus F-21 (Table S2), however it did not inhibit the growth of E.coli 251. The minimal inhibition concentration level is comparable with other similar piperidine derivatives (Issayeva, Datkhayev et al. 2019). Among most widely used anti tubercular drugs is isonicotinic acid hydrazide (Isoniazide) and its derivatives (Koçyiğit-Kaymakçoğlu, Oruç-Emre et al. 2009, Sterling, Moro et al. 2015, Vilchêze and Jacobs Jr 2019, Zhang, Jiang et al. 2019). Therefore, following study will be devoted to testing of these derivatives: (2-(N-piperidinyl)acetic acid hydrazide and 3,4-dihydroxybenziliden hydrazide 2-methyl-3-(N-piperidinyl)propionic acid BDVI against M.Tuberculosis. Spasmolytic activity of compounds MAI, MAII, BDIII and BDIV were tested *in vitro* (Table 2). Active pharmaceutical substances MAI, MAII and DBIII revealed spasmolytic activity comparable to the activity of model drug Dotraverin. Taking into account that LD50 mmol/kg of novel substances more than 100 times less than model drugs illustrated in Table 1 these derivatives can be recommended for medical use at least in veterinary and recommended for comprehensive nonclinical studies. *In vivo* testing of the compounds MAI, MAII, BDIII and BDIV showed a spasmolytic activity comparable to a model drug – Dotraverin. LD50 mmol/kg 100 times less than the model drug is suitable for veterinary and medical uses. The derivative BDIV illustrated spasmolytic activity under acetylcholine induced spasm, however 2-methyl-3-(N-morpholyl) propionic acid hydrazide was less active compared to the drug of comparison. The substitution of piperidine ring to morpholine moiety lead to a decreased of spasmolytic activity (Table 2). The incorporation of the spacer $>CH(CH_3)$ between heterocycle and hydrazide group did not affect the activity. Based on obtained biological screening, it was found that piperidine containing derivatives showed significant spasmolytic activity. The predicted

Table 2
Spasmolytic activity of synthesized compounds MAI, MAII, DBIII and DBIV tested *in vitro*.

Pharmaceutical active substance	Change in intestinal length after drug administration	Acetylcholine spasm (1 mg Acetylcholine / 1 ml medium)	Histamine spasm activity (1 mg Histamine / 1 ml medium)
MAI	0	0	0
MAII	0	Increased by 4 mm	Increased by 4 mm
BDIII	0	0	0
BDIV	Diminished by 3 mm	Increased by 2 mm	Diminished by 3 mm
Dotraverin	0	0	0
Acetylcholine	–	Diminished by 4 mm	–
Histamine	–	–	Increased by 4 mm

Table 3
Predicted probability of pharmacological activity using PASS software.

Pharmaceutical active substance	Pa	Pi	Pharmacological activity
MAI C ₇ H ₁₅ N ₃ O	0.310	0.053	Muscle relaxant
BDIII C ₉ H ₁₉ N ₃ O	0.405	0.029	Muscle relaxant
BDIII C ₉ H ₁₉ N ₃ O	0.345	0.013	Central nervous system active muscle relaxant
BDIII C ₉ H ₁₉ N ₃ O	0.372	0.038	Skeletal muscle relaxant
BDIV C ₈ H ₁₇ N ₂ O ₂	0.357	0.040	Muscle relaxant
BDIV C ₈ H ₁₇ N ₃ O ₂	0.393	0.008	Central nervous system active muscle relaxant
MAI C ₇ H ₁₅ N ₃ O	0.843	0.011	Nootropic
MAII C ₉ H ₂₀ N ₄ O ₂	0.633	0.063	Nootropic
BDIII C ₉ H ₁₉ N ₃ O	0.555	0.098	Nootropic
BDIV C ₈ H ₁₇ N ₃ O ₂	0.467	0.158	Nootropic
MAI C ₇ H ₁₅ N ₃ O	0.684	0.031	Antischematic. cerebral
MAII C ₉ H ₂₀ N ₄ O ₂	0.804	0.014	Antischematic. cerebral
BDIII C ₉ H ₁₉ N ₃ O	0.716	0.026	Antischematic. cerebral
BDIV C ₈ H ₁₇ N ₃ O ₂	0.730	0.024	Antischematic. cerebral
MAI C ₇ H ₁₅ N ₃ O	0.655	0.013	Anticonvulsant
MAII C ₉ H ₂₀ N ₄ O ₂	0.521	0.031	Anticonvulsant
BDIII C ₉ H ₁₉ N ₃ O	0.461	0.045	Anticonvulsant
BDIV C ₈ H ₁₇ N ₂ O ₂	0.501	0.035	Anticonvulsant
MAI C ₇ H ₁₅ N ₃ O	0.536	0.074	Kidney function stimulant
BDIII C ₉ H ₁₉ N ₃ O	0.431	0.145	Kidney function stimulant
MAI C ₇ H ₁₅ N ₃ O	0.570	0.046	Antidyskinetic
BDIII C ₉ H ₁₉ N ₃ O	0.425	0.090	Antidyskinetic
MAI C ₇ H ₁₅ N ₃ O	0.518	0.034	Respiratory analeptic
BDIII C ₉ H ₁₉ N ₃ O	0.469	0.045	Respiratory analeptic
BDIV C ₈ H ₁₇ N ₃ O ₂	0.499	0.038	Respiratory analeptic

activity level is represented in PASS software by the list of activities with the probabilities “to be active” (Pa) and “to be inactive” (Pi) generated for each biological activity. The obtained data is in excellent agreement with PASS software prediction data illustrating that substances MAI and BDIII should possess spasmolytic, urinary and spasmolytic activity with probabilities (Pa) of 0,426 & 0,34 and 0,400 & 0,516, respectively. The transformation of hydrazide group to hydrazone does not decrease the probability of spasmolytic activity and the pharmaceutically active substance BDIV has a coefficient of 0.511. Piperidine derivative MAI (Pa 0.498) BDIII (Pa 0.537) and DBIV (Pa 0.433) possesses high probability of the Cytochromes P450 activator gene CYP2E1 inducing activity and therefore it would be interesting to check it *in vivo* studies in further study. Piperidine derivative MAI (Pa 0.498) BDIII (Pa 0.537) and DBIV (Pa 0.433) possess a high probability of inducing the expression of the CYP2E1 gene, which is a Cytochrome P450 activator. This lays an interest in the further studies to check that activity. Comparative analysis of predicted pharmacological activity of piperidine and morpholine derivatives revealed in Table 3. There is a report that secondary and tertiary amines were conveniently synthesized by alkylating amines of pyrrolidine, piperidine, morpholine, furfurylamine etc. with the applicable alkyl bromides, such as isoamyl bromide, 2-bromo-6-methyl-heptane, arid 2-bromo-6-methylhept-5-ene and none of them revealed superior spasmolytic activity to either atropine or papaverine (Cocolas, Avakian et al. 1965).

4. Conclusion

It was illustrated that heterocyclic compounds 2-(N-piperidinyl)acetic acid hydrazide and 2-methyl-3-(N-piperidinyl) propionic acid hydrazide have high antimicrobial and spasmolytic activity concurrently with low toxicity. It was established that obtained hydrazides containing morpholinyl moiety did not possess antimicrobial and spasmolytic activity at tested range of concentrations. Nevertheless, synthesized heterocyclic derivatives have low acute toxicity and therefore perspective for study other

type of activities. 3,4-dihydroxybenzylidenhydrazide 2- methyl-3-(N-piperidinyl)propionic acid may be used as a prodrug for delivery of active compound BDIII generated via hydrolysis under acidic conditions. 3,4-dihydroxy-benzylidenhydrazide 2-methyl-3-(N-piperidinyl)propionic acid can be perspective for study its antioxidant and anticancer activity due to presence of phenolic hydroxyl groups. It was observed that the introduction of methylene groups between heterocycle and hydrazide group led to significant decrease of antimicrobial activity. 2-methyl-(3-N-piperidinyl)propionic acid hydrazide did not show antifungal activity against *C. albicans*, *A. flavus*, *M. canis*, *F. solani*, *C. glabrata*. The following study will be devoted to comprehensive study of the mechanism of analgesic and spasmolytic activity of these heterocyclic hydrazides.

CRedit authorship contribution statement

Dmitriy A. Berillo: Data curation, Conceptualization, Visualization. **Moldyr A. Dyusebaeva:** Data curation.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement

This research was supported by the internal University research grant Afendiyarov KazNMU. "Chemical development and research of active pharmaceutical substances based on nitrogen-containing heterocyclic compounds".

Appendix A. Supplementary material

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jsps.2022.04.009>.

References

- Alanine, A., Anselm, L., Steward, L., Thomi, S., Vifian, W., Groaning, M.D., 2004. Synthesis and SAR evaluation of 1, 2, 4-triazoles as A2A receptor antagonists. *Bioorg. Med. Chem. Lett.* 14 (3), 817–821. <https://doi.org/10.1016/j.bmcl.2003.09.095>.
- Ben Arfa, A., Combes, S., Preziosi-Belloy, L., Gontard, N., Chalier, P., 2006. Antimicrobial activity of carvacrol related to its chemical structure. *Lett. Appl. Microbiol.* 43 (2), 149–154. <https://doi.org/10.1111/j.1472-765X.2006.01938.x>.
- Berillo, D. (2010). "Synthesis, structure and properties of hydrazides of aminopropane acid and their derivatives." PhD thesis.
- Berillo, D. and Ahmedova Sh.S. (2008). "Synthesis of 2-methyl-(3N-morpholy)propan acid hydrazide and their properties." Proceedings of the VI International Beremzhanov Congress on Chemistry and Chemical Technology, 534–538.
- Cebeci, Y.U., Bayrak, H., Şirin, Y., 2019. Synthesis of novel Schiff bases and azol-β-lactam derivatives starting from morpholine and thiomorpholine and investigation of their antitubercular, antiurease activity, acetylcholinesterase inhibition effect and antioxidant capacity. *Bioorg. Chem.* 88, 102928. <https://doi.org/10.1016/j.bioorg.2019.102928>.
- Coccolas, G.H., Avakian, S., Martin, G.J., 1965. Synthetic Spasmolytic Amines. *J. Med. Chem.* 8 (6), 875–877. <https://doi.org/10.1021/jm00330a038>.
- Council, N. R. (2010). Guide for the care and use of laboratory animals, National Academies Press.
- Council, N.R., 2011. Animal care and use program. Guide for the Care and Use of Laboratory Animals. National Academies Press (US).
- Di Braccio, M., Grossi, G., Alfei, S., Ballabeni, V., Tognolini, M., Flammini, L., Giorgio, C., Bertoni, S., Barocelli, E., 2014. 1, 8-Naphthyridines IX. Potent anti-inflammatory and/or analgesic activity of a new group of substituted 5-amino [1, 2, 4] triazolo [4, 3-a][1, 8] naphthyridine-6-carboxamides, of some their Mannich base derivatives and of one novel substituted 5-amino-10-oxo-10H-pyrimido [1, 2-a][1, 8] naphthyridine-6-carboxamide derivative. *Eur. J. Med. Chem.* 86, 394–405. <https://doi.org/10.1016/j.ejmech.2014.08.069>.
- Domagala, J.M., 1994. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. *J. Antimicrob. Chemother.* 33 (4), 685–706. <https://doi.org/10.1093/jac/33.4.685>.
- Dudek, A.Z., Arodz, T., Gálvez, J., 2006. Computational methods in developing quantitative structure-activity relationships (QSAR): a review. *Comb. Chem. High Throughput Screening* 9 (3), 213–228. <https://doi.org/10.2174/138620706776055539>.
- Dyusebaeva, M., Elibaeva, N., Kalugin, S., 2017. Antimicrobial Activity of 1, 2, 5 Trimethylpiperidin-4-OI Derivatives. *Pharm. Chem. J.* 51 (7), 550–552. <https://doi.org/10.1007/s11094-017-1652-x>.
- Dyusebaeva, M. and S. Kalugin (2015). "Thiosemicarbazides of piperidylacetic acid in the synthesis of bisheterocyclic compounds." *Russian J. General Chem.* 85(7), 1775–462 1778.
- El-Shamy, I.E., Abdel-Mohsen, A., Alsheikh, A.A., Fouda, M.M., Al-Deyab, S.S., El-Hashash, M.A., Jancar, J., 2015. Synthesis, biological, anti-inflammatory activities and quantum chemical calculation of some [4-(2, 4, 6-trimethylphenyl)-1 (2H)-oxo-phthalazin-2yl]acetic acid hydrazide derivatives. *Dyes Pigm.* 113, 357–371. <https://doi.org/10.1016/j.dyepig.2014.08.026>.
- Eswaran, S., Adhikari, A.V., Shetty, N.S., 2009. Synthesis and antimicrobial activities of novel quinoline derivatives carrying 1, 2, 4-triazole moiety. *Eur. J. Med. Chem.* 44 (11), 4637–4647. <https://doi.org/10.1016/j.ejmech.2009.06.031>.
- Gegia, M., Winters, N., Benedetti, A., van Soolingen, D., Menzies, D., 2017. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. *Lancet. Infect. Dis* 17 (2), 223–234.
- Gein, V.L., Odegova, T.F., Yankin, A.N., Nosova, N.V., 2015. Synthesis and Antimicrobial Activity of N,N',2-Triaryl-6-Hydroxy-6-Methyl-4-Oxocyclohexane-1,3-Dicarboxamides. *Pharm Chem J* 49 (4), 246–249.
- Hooser, S., Beasley, V.R., Lovell, R., Carmichael, W., Haschek, W., 1989. Toxicity of microcystin LR, a cyclic heptapeptide hepatotoxin from *Microcystis aeruginosa*, to rats and mice. *Vet. Pathol.* 26 (3), 246–252. <https://doi.org/10.1177/030098588902600309>.
- Issayeva, U. B., U. M. Datkhayev, K. D. Praliyev, G. S. Akhmetova and O. M.T. (2019). "Synthesis of biologically active phenoxypropargylpiperidine with fragments of small cycles Buletin KazNMU.
- Jachak, G.R., Ramesh, R., Sant, D.G., Jorwekar, S.U., Jadhav, M.R., Tupe, S.G., Deshpande, M.V., Reddy, D.S., 2015. Silicon incorporated morpholine antifungals: design, synthesis, and biological evaluation. *ACS Med. Chem. Lett.* 6 (11), 1111–1116. <https://doi.org/10.1021/acsmedchemlett.5b00245>.
- Karaman, N., Oruç-Emre, E.E., Sıcak, Y., Çatıkkaş, B., Karaküçük-İyidoğan, A., Öztürk, M., 2016. Microwave-assisted synthesis of new sulfonyl hydrazones, screening of biological activities and investigation of structure-activity relationship. *Med. Chem. Res.* 25 (8), 1590–1607. <https://doi.org/10.1007/s00044-016-1592-0>.
- Kocyiğit-Kaymakçioğlu, B., Oruç-Emre, E.E., Unsalan, S., Rollas, S., 2009. Antituberculosis activity of hydrazones derived from 4-fluorobenzoic acid hydrazide. *Med. Chem. Res.* 18 (4), 277–286. <https://doi.org/10.1007/s00044-008-9126-z>.
- Kulkarni, S. K., C. S. Patil, N. K. Jain and A. Singh (2004). Modulatory effect of diclofenac on antispasmodic effect of pitofenone in cholinergic spasm.
- Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv. Drug Deliv. Rev.* 23 (1–3), 3–25. [https://doi.org/10.1016/s0169-409x\(00\)00129-0](https://doi.org/10.1016/s0169-409x(00)00129-0).
- Mathew, B., Suresh, J., Ahsan, M.J., Mathew, G.E., Usman, D., Subramanian, P.N.S., Safna, K.F., Maddela, S., 2015. Hydrazones as a privileged structural linker in antitubercular agents: A review. *Infect. Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders)* 15 (2), 76–88. <https://doi.org/10.2174/1871526515666150724104411>.
- Middlebrook, G., 1954. Isoniazid-resistance and catalase activity of tubercle bacilli: a preliminary report. *Am. Rev. Tuberculosis* 69 (3), 471–472.
- Misra, R., C. Dwivedi, S. Parmar and S. Singh (1978). Synthesis of 1-(N-acetyl-piperidino)-4-aryl semicarbazides as possible anticonvulsants. *J. Heterocyclic Chem.* 15(4), 681–682.
- Mittendorf, J., Kunisch, F., Matzke, M., Militzer, H.-C., Schmidt, A., Schönfeld, W., 2003. Novel antifungal β-amino acids: synthesis and activity against *Candida albicans*. *Bioorg. Med. Chem. Lett.* 13 (3), 433–436. [https://doi.org/10.1016/S0960-894X\(02\)00958-7](https://doi.org/10.1016/S0960-894X(02)00958-7).
- Narang, R., Narasimhan, B., Sharma, S., 2012. A review on biological activities and chemical synthesis of hydrazide derivatives. *Curr. Med. Chem.* 19 (4), 569–612. <https://doi.org/10.2174/092986712798918789>.
- Pillai, M.V., Rajeswari, K., Vidhyasagar, T., 2014. Stereoselective synthesis, spectral and antimicrobial studies of some cyanoacetyl hydrazones of 3-alkyl-2, 6-518 diarylpiperidin-4-ones. *J. Mol. Struct.* 1076, 174–182. <https://doi.org/10.1016/j.molstruc.2014.07.050>.
- Popiołek, L., 2017. Hydrazide-hydrazones as potential antimicrobial agents: overview of the literature since 2010. *Med. Chem. Res.* 26 (2), 287–301. <https://doi.org/10.1007/s00044-016-1756-y>.
- Rips, R., Derappe, C., Magnin, P., 1965. Chemical Structure and Pharmacological Activity of Glycine Derivatives. Influence of Disubstitution of the Amine Function of Glycine Esters and Hydrazides Ia. *J. Med. Chem.* 8 (4), 529–531.
- Rollas, S., & Küçükgüzel, S.G. (2007). Biological activities of hydrazone derivatives. *Molecules*, 12(8), 1910–1939.
- Ross, R.R., 1958. "Use of pyridoxine hydrochloride to prevent isoniazid toxicity." *Journal of the Am. Med. Assoc.* 168 (3), 273–275. <https://doi.org/10.1001/jama.1958.63000030004011a>.
- Roveda, J.-G., Clavette, C., Hunt, A.D., Gorelsky, S.I., Whipp, C.J., Beauchemin, A.M., 2009. Hydrazides as tunable reagents for alkene hydroamination and aminocarbonylation. *J. Am. Chem. Soc.* 131 (25), 8740–8741.
- Sader, H.S., Castanheira, M., Huband, M., Jones, R.N., Flamm, R.K., 2017. WCK 5222 (cefepime-zidebactam) antimicrobial activity against clinical isolates of Gram-

- negative bacteria collected worldwide in 2015. *Antimicrob. Agents Chemother.* 61 (5), e00072–00017. <https://doi.org/10.1128/AAC.00072-17>.
- Sensi, P., Maggi, N., Ballotta, R., Fürész, S., Pallanza, R., Arioli, V., 1964. Rifamycins. 1 XXXV. 2 Amides and hydrazides of rifamycin B3. *J. Med. Chem.* 7 (5), 596–602.
- Shah, B.R., Santucci, K., Sinert, R., Steiner, P., 1995. Acute isoniazid neurotoxicity in an urban hospital. *Pediatrics* 95 (5), 700–704.
- Sievers, M.L., Herrier, R.N., 1975. Treatment of acute isoniazid toxicity. *Am. J. Hospital Pharm.* 32 (2), 202–206.
- Stasevych, M., V. Zvarych, V. Lunin, N. Deniz, Z. Gokmen, O. Akgun, E. Ulukaya, V. Poroikov, T. Glorizova and V. Novikov (2017). "Computer-aided prediction and cytotoxicity evaluation of dithiocarbamates of 9, 10-anthracenedione as new anticancer agents." SAR and QSAR Environm. Res. 28(5), 355–366. doi.org/10.1080/1062936X.2017.1323796.
- Sterling, T.R., Moro, R.N., Borisov, A.S., Phillips, E., Shepherd, G., Adkinson, N.F., Weis, S., Ho, C., Villarino, M.E., 2015. Flu-like and other systemic drug reactions among persons receiving weekly rifampentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT tuberculosis study. *Clin. Infect. Dis.* 61 (4), 527–535. <https://doi.org/10.1093/cid/civ323>.
- Tikhov, R.M., Kuznetsov, N.Y., 2020. Construction of piperidine-2,4-dione-type azaheterocycles and their application in modern drug development and natural product synthesis. *Org. Biomol. Chem.* 18 (15), 2793–2812. <https://doi.org/10.1039/D0OB00287A>.
- Tolstikova, O.V., Tolstikov, A.G., Shmakov, V.S., Galkin, E.G., Abdrakhmanov, I.B., Aripova, S.F., 1988. Total synthesis of racemic diptocarpidine and diptocarpiline. *Chem. Nat. Compd.* 24 (1), 66–70.
- Vilchèze, C., Jacobs, W.R., 2019. The isoniazid paradigm of killing, resistance, and persistence in *Mycobacterium tuberculosis*. *J. Mol. Biol.* 431 (18), 3450–3461. <https://doi.org/10.1016/j.jmb.2019.02.016>.
- Zhang, T., G. Jiang, S. a. Wen, F. Huo, F. Wang, H. Huang and Y. Pang (2019). "Para-aminosalicylic acid increases the susceptibility to isoniazid in clinical isolates of *Mycobacterium tuberculosis*." *Infection and drug resistance* 12: 825. <https://doi.org/10.2147/IDR.S200697>.